Latest Conference Articles

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

Pharmacists play a pivotal role working alongside the DEA and OIG in enforcing and preventing drug diversion nationally.

An FDA executive discusses the Surgeon General’s recommendations for promoting mental health and wellbeing for employees in the workplace.

A pharmacist discusses the impact of comprehensive weight management with a shared decision making approach.

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Studies have shown that the presence of advanced pharmacy technicians in a pharmacy has a positive predictive validity to increased monthly immunizations.

Food pharmacies, in particular, can be a great opportunity for pharmacists to collaborate with other providers, improve access to nutritious foods, and find unique opportunities to counsel patients.

Shared decision making with patients is a key component of RSV vaccination, which can bring challenges and opportunities.

In addition to improved efficacy, newer generations of anti-obesity medications have significantly improved safety concerns.

Sa'ed Al-Olimat, PharmD, also discussed the potentially groundbreaking shift for MDMA expected later in 2024.

Pharmacogenomics could help streamline prescribing and dosing for psychiatric medications, avoiding the trial-and-error process common with these medications.

Pharmacists can educate patients on current clinical evidence of cannabis’s therapeutic benefit, as well as cannabis’s complexities, risks, and potential adverse effects.

Expert Jennifer Clements discussed the evolving landscape of weight management medications, clinical considerations, and obstacles to use.

As more states have legalized cannabis use—both medicinal and recreational—Sera said pharmacists’ roles in counseling will become even more important.

Holloway discusses gender-affirming care, the challenging current legal landscape, and in particular how pharmacists can best serve their patients who are transgender or gender diverse.

Identifying the best uses for these tools, whether in patient education, data collection, improving efficiencies, or other uses, could significantly improve the future of pharmacy.

Lakdawala and Vernon’s session discusses the changing landscape of hormonal contraception and pharmacists’ roles within it.

The data comes from 2 phase 4 trials, ENABLE and EMPOWER, which evaluated lanadelumab and the outcomes of treatment in adolescents with hereditary angioedema.

Nazia Somani Babul, PharmD, BCACP, discussed her presentation about nontraditional pharmacy models, and particularly a model at her facility focused on comprehensive pain management counseling.

Mila Felder, MD, FACEP, discusses Advocate Aurora Health’s approach to addressing burnout among health care professionals in health care systems.

Women who have longer ovarian function and enter menopause later in life tend to live longer, according to women’s health researcher.

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

This treatment improved the severity of symptoms in patients with scalp and nail psoriasis.

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.

Health span, wealth span, advocacy, and ethics are all burgeoning topics within the field of longevity.

Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

The CORe initiative is aimed at promoting inclusivity, reducing startup time for clinical trials, and facilitating data sharing to address recruitment and retention challenges in cancer research at community oncology sites.